explore -WSS

explore

author：Wikipedia 2025-09-30 22:10:06 - browse：8

Verve Therapeutics CEO Sekar Kathiresan Verve

SAN FRANCISCO — The promise of genome editing has given rise to potentially curative medicines for rare, life-threatening diseases that generally affect small numbers of patients. But since Verve Therapeutics was founded in 2018, it’s had a wider aperture: using the molecular tools of genome editing to go after the most common cause of death in the world.

The plan, according to Verve CEO Sekar Kathiresan, is to edit out heart attacks for the millions of people at risk for severe cardiovascular disease. It’s a goal that’s more than a little audacious. There’s just one approved genome editing medicine, a treatment for sickle cell disease, and it only passed Food and Drug Administration review last month. Base editing, the CRISPR successor Verve uses to conduct its molecular surgery, is only a few years old.

“When we started, there were so many things that we were kind of going against the grain on,” Kathiresan told STAT at the J.P. Morgan Healthcare Conference in San Francisco this week. “In 2018, it was all about platforms, not about specific diseases and products, or taking this kind of idea for a large indication as opposed to cancer or rare disease. But we’ve always been motivated by a deep conviction in one simple research insight, which is that if your blood cholesterol is really low, lifelong, it is very hard to get a heart attack.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Study fuels hope CAR

hotspot

knowledge

WSS

Creating egg and sperm cells from stem cells raises ethical issues

5 to watch: Tech startups trying to solve health care's staffing crisis

CDC advisory group OKs chikungunya vaccine

'Vaccine

Future doctors should be trained to promote social change

Childhood vaccination ad campaign launches in the U.K.

entertainment

explore

knowledge

In age of alternative facts, a scholarly course on calling out crap

Baby aspirin cuts fat buildup in liver disease patients, in small study

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Sports medicine is finally prioritizing gender equality

Change Healthcare cyberattack shows risk of industry consolidation

ChatGPT in medicine: STAT answers readers' burning questions

SCOTUS questions limit to govt efforts to fight misinformation

Medicare details structure of new drug price negotiation program

CDC panel: People 65 and older should get a Covid spring booster shot

knowledge

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Future doctors should be trained to promote social change

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Stop the failed accountable care organization experiment

SCOTUS questions limit to govt efforts to fight misinformation

hotspot

knowledge

knowledge

hotspot